Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Receivables (2016 - 2025)

China Pharma Holdings' Change in Receivables history spans 16 years, with the latest figure at -$13.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 6444.99% year-over-year to -$13.5 million; the TTM value through Dec 2025 reached -$13.2 million, down 6780.77%, while the annual FY2025 figure was -$13.2 million, 6780.77% down from the prior year.
  • Change in Receivables reached -$13.5 million in Q4 2025 per CPHI's latest filing, down from $117491.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $434306.0 in Q1 2023 to a low of -$13.5 million in Q4 2025.
  • Average Change in Receivables over 5 years is -$567847.9, with a median of $113758.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: soared 578.17% in 2022, then plummeted 6444.99% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $393662.0 in 2021, then plummeted by 72.75% to $107286.0 in 2022, then soared by 239.52% to $364258.0 in 2023, then tumbled by 41.54% to $212942.0 in 2024, then tumbled by 6444.99% to -$13.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Change in Receivables are -$13.5 million (Q4 2025), $117491.0 (Q3 2025), and $20566.0 (Q2 2025).